Business Update on the FDA Investigational Device Exemption (IDE) Regulatory Submission for RadioGel® Precision Radionuclide Therapy™
Vivos Inc. Completes Enrollment in Study of Postoperative Precision Radionuclide Therapy for Incomplete Tumor Resection
Vivos Inc. Reports Positive Independent Drug Elution Data Validating PrecisionGel™ for Sustained Localized Delivery
Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™
Vivos Inc. (OTCQB: RDGL) Announces Receipt of Washington State Radioactive Materials License for IsoPet ® Manufacturing
Vivos Inc. Announces Acceptance of Abstract for Presentation at the American College of Veterinary Surgeons (ACVS) Surgical Summit
